News Center
-91.jpg)
-
LM-102 Obtained FDA Clinical Trial Approval and Completed First Patient Dosing
LM-102 obtained FDA clinical trial approval early this year as a phase I clinical study designed to evaluate the safety and initial efficacy of LM-102.
2021-06-22Learn More
-
LM-302 Obtained FDA Clinical Trial Approval
Claudin 18.2 ADC LM-302 obtained US FDA clinical study approval. This study is a multi-center clinical study designed to evaluate the safety and initial efficacy of LM-302.
2021-06-21Learn More
-
LM-302 Obtained FDA Orphan Drug Designation
Claudin 18.2 ADC LM-302 obtained FDA Orphan Drug Designation in May 2021 for indications of pancreatic, gastric, and gastroesophageal junction cancers.
2021-05-12Learn More
-
LaNova Medicines Successfully Completed Series A Financing
In November 2020, LaNova Medicines completed the series A financing with Qiming Venture Partners as the leading investor and China Renaissance as the financial adviser. Investors also include global or domestic well-known PE / VCs, such as TF Capital, Yin
2020-12-12Learn More